Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desmopressin for reduction of postoperative blood loss in children with congenital cyanotic heart disease undergoing cardiopulmonary bypass
PACTR202004798675261Phase 0Recruiting
- Sponsor
- Mansoura University Children Hospital
- Start
- Apr 2020
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 0 trial of desmopressin in Cyanotic heart disease (CCHD) (2 arms), sponsored by Mansoura University Children Hospital. Primary endpoint: Total postoperative blood loss in first 24 hours. Started Apr 2020; status: recruiting.
02
Drugs
desmopressin
03
Conditions
Cyanotic heart disease (CCHD)
Beyond the preview
Go deeper on PACTR202004798675261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202004798675261.